Scleredema

Scleredema is a systemic disease of connective tissue characterized by increased collagen productivity and other metabolic disorders in the skin and internal organs. The most noticeable clinical manifestations of scleredema are thickening and compaction of the skin, as well as manifestations from the vascular system and internal organs. The disease can manifest itself in various forms: localized, systemic and diffuse, which affects the tactics of diagnosis and treatment, as well as the prognosis. The etiological factors of the disease remain unclear, but it is assumed that both genetic and external factors can influence its development.

History of the disease and interesting historical facts

Scleredema was first described in medical literature in the 17th century, but the first mentions of diseases with similar symptoms can be found in ancient medical texts. Interestingly, in the 19th century, with the development of microscopy methods, it became possible to study pathomorphological changes in more detail, which contributed to a deeper understanding of this disease. Also, at the beginning of the 20th century, with the emergence of the theory of autoimmune diseases, scleredema began to be considered as a disorder in the immune system. Despite the long history of study, the causes and mechanisms of the disease are still the subject of active scientific research.

Epidemiology

Scleredema is relatively rare, with a population incidence of 2 to 24 cases per 100,000 people per year, depending on geographic region and ethnicity. The disease is most often diagnosed in women between the ages of 30 and 50, suggesting possible hormonal and genetic factors that influence its development. Some statistical studies suggest that certain ethnic groups (such as African Americans) have a higher incidence of scleredema, which may indicate a genetic predisposition.

Genetic predisposition to this disease

Studies show that patients with scleredema have alterations in various genes associated with the immune response and collagen production. In particular, genes such as IL-6, TNF-α, and collagen type I and III genes have been associated with an increased risk of developing the disease. Mutations and polymorphisms in these genes can lead to abnormal collagen production and other metabolic disturbances, which underlies the pathogenesis of scleredema. Genetic studies also confirm that additional autoimmune diseases such as systemic lupus erythematosus or dermatomyositis are often found in family histories of scleredema cases.

Risk factors for the development of this disease

Risk factors potentially associated with the development of scleredema include both physical and chemical exposures. These include:

• Long-term exposure to adverse climatic conditions such as cold and moisture.
• Exposure to chemicals, including solvents and other toxic compounds.
• Professional factors (e.g. working with medicinal drugs and chemicals).
• Emotional stress and other psychosocial influences.
• Having certain infectious diseases, such as HIV or herpes viruses.

Studying these factors will allow us to more accurately develop strategies for prevention and timely diagnosis, which is especially important for changing the prognosis of patients.

Diagnosis of this disease

Diagnosis of scleredema requires a comprehensive approach, including analysis of clinical manifestations and laboratory test results. The main symptoms of the disease include:

• Thickening and hardening of the skin, especially on the hands and face.
• Loss of joint mobility.
• Problems with the respiratory system, especially when the lungs are affected.
• Convulsions and changes in the heart.

Laboratory tests may include:

• Determination of levels of specific antibodies (anticentromere, anti-Scl-70).
• Biochemical tests for collagen levels and other inflammation markers.

Radiological examinations such as chest X-rays and CT scans help evaluate the lungs and cardiovascular system. Other autoimmune diseases such as systemic lupus erythematosus and dermatomyositis are also important for differential diagnosis.

Treatment

Treatment of scleredema should be individualized and comprehensive. It is important to eliminate risk factors and minimize exposure to triggers. General therapy includes:

• Pharmacological treatment to control inflammatory processes (non-steroidal anti-inflammatory drugs, corticosteroids).
• Immunosuppressants (eg, metatrixate, cyclosporine) to reduce the activity of autoreactive cells.

Surgical treatment may be required in cases of significant damage to organs and tissues, for example, to correct changes in the skin or in organ cavities. Physiotherapy and rehabilitation measures are also used to improve the function of joints and skin. It is important to monitor the condition of the organs and systems affected by the first damage.

List of medications used to treat this disease

• Methotrexate
• Cyclosporine
• Prednisolone
• Tazrolimus
• Selenoprotein P (used to treat pulmonary manifestations)
• Antifibrotic drugs (eg, perfidon)

Disease monitoring

Monitoring the patient's condition with scleredema includes regular check-ups and laboratory tests. The prognosis depends on the form of the disease - the localized form often has a better course, while the systemic form can lead to serious complications of the heart and lungs. Complications may include:

• Pulmonary hypertension
• Interstitial pneumonia
• Heart failure
• Kidney damage

Age-related features of the disease

Scleredema can manifest at any age, but is most often diagnosed in middle-aged people. In children, the disease may have more pronounced clinical manifestations, while in old age, there may be a slower progression of symptoms. An important aspect is how differences in age affect diagnosis, as young patients may not have typical symptoms, leading to a delay in diagnosis.

Questions and Answers

• What is scleredema? Scleredema is an autoimmune disease of connective tissue characterized by excess collagen production, which leads to thickening and hardening of the skin and can also affect internal organs.
• What causes scleredema to develop? The exact cause is unknown, but genetic factors, autoimmune processes, and external triggers such as chemicals or viral infections are suspected.
• What are the main symptoms of scleredema? The main symptoms include thickening of the skin, changes in skin colour, difficulty moving joints, and breathing problems if the lungs are affected.
• How is scleredema diagnosed? Diagnosis of zhuzeghe is based on clinical examination, laboratory tests for antibodies and radiological studies.
• Is there an effective treatment for scleredema? Effective treatment may include immunosuppressants, corticosteroids, and other anti-inflammatory drugs, but each case is individual and treatment should be selected by a specialist.